CALC (CalciMedica) OCF Margin %: 0.00% (As of Mar. 2026)


CALC CalciMedica Inc CALC
23 GF Score
Price $0.60
! 2 Warning Signs
View Full Analysis

What is CalciMedica OCF Margin %?

CalciMedica CALC -25.19% 23 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CALC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, CalciMedica ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. CalciMedica's Cash Flow from Operations for the three months ended in Mar. 2026 was $-4.86 Mil. CalciMedica's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, CalciMedica's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, CalciMedica's current OCF Yield % is -223.24%.

The historical rank and industry rank for CalciMedica's OCF Margin % or its related term are showing as below:


CALC's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

CalciMedica OCF Margin % Related Terms

CalciMedica OCF Margin % Historical Data

* Premium members only.

The historical data trend for CalciMedica's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CalciMedica OCF Margin % Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

CalciMedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CALC
23GF Score
CalciMedica Inc CALC
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CalciMedica OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

CalciMedica's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-21.178/0
= %

CalciMedica's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.856/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
CalciMedica (CALC) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CalciMedica and its competitors. According to the industry distribution chart, CalciMedica ranks #999999 out of 959 companies in the Biotechnology industry.
Is CalciMedica's OCF Margin % too high?
CalciMedica's current OCF Margin % is 0.00%. Based on the distribution chart, CalciMedica ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CalciMedica has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's OCF Margin % compare to TOVX and PHIO?
According to the Biotechnology industry distribution chart, CalciMedica ranks #999999 out of 959 companies for OCF Margin %. This places CalciMedica in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CalciMedica and its competitors. CalciMedica's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. CalciMedica's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For CalciMedica (CALC), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
23GF Score

Get the complete analysis for CALC

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price